(Q34538249)

English

Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled perio

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled perio (English)

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

0 references

0 references

0 references

0 references

1 reference

based on heuristic

inferred from title

psoriatic arthritis

1 reference

based on heuristic

inferred from title

monoclonal antibody

1 reference

based on heuristic

inferred from title

0 references

Désirée van der Heijde

2

object named as

Désirée van der Heijde

0 references

Dafna D. Gladman

10

object named as

Dafna D Gladman

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

author name string

Philip J Mease

1

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Christopher T Ritchlin

3

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Masato Okada

4

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Raquel S Cuchacovich

5

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Catherine L Shuler

6

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Chen-Yen Lin

7

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Daniel K Braun

8

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Chin H Lee

9

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

SPIRIT-P1 Study Group

11

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

language of work or name

0 references

publication date

23 August 2016

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Annals of the Rheumatic Diseases

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

76

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

79-87

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Psychometric properties of the Itch Numeric Rating Scale in patients with moderate-to-severe plaque psoriasis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5264219

7 July 2018

Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5264219

7 July 2018

Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5264219

7 July 2018

Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5264219

7 July 2018

Current concepts in psoriatic arthritis: pathogenesis and management

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5264219

7 July 2018

Interleukin-17+CD8+ T cells are enriched in the joints of patients with psoriatic arthritis and correlate with disease activity and joint damage progression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5264219

7 July 2018

Angiogenic and inflammatory properties of psoriatic arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5264219

7 July 2018

Immunomodulation in psoriatic arthritis: focus on cellular and molecular pathways

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5264219

7 July 2018

Role of IL-17 in psoriasis and psoriatic arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5264219

7 July 2018

Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5264219

7 July 2018

Circulating Th17, Th22, and Th1 cells are increased in psoriasis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5264219

7 July 2018

Psoriatic arthritis as a distinct disease entity.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5264219

7 July 2018

Development of an assessment tool for dactylitis in patients with psoriatic arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5264219

7 July 2018

Psoriasis assessment tools in clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5264219

7 July 2018

Psoriatic arthritis imaging: a review of scoring methods

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5264219

7 July 2018

Psoriatic arthritis: epidemiology, clinical features, course, and outcome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5264219

7 July 2018

Nail Psoriasis Severity Index: a useful tool for evaluation of nail psoriasis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5264219

7 July 2018

Psoriatic arthritis.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209709

21 January 2018

American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209709

21 January 2018

Psoriasis disease severity measures: comparing efficacy of treatments for severe psoriasis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209709

21 January 2018

Measurement of patient outcome in arthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209709

21 January 2018

Minimally important difference of Health Assessment Questionnaire in psoriatic arthritis: relating thresholds of improvement in functional ability to patient-rated importance and satisfaction

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209709

21 January 2018

Requirement of interleukin-17A for systemic anti-Candida albicans host defense in mice

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209709

21 January 2018

Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5264219

27 October 2018

Measuring dactylitis in clinical trials: which is the best instrument to use?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5264219

27 October 2018

Anti–Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2016-209709

21 January 2018

Measuring clinical enthesitis in psoriatic arthritis: assessment of existing measures and development of an instrument specific to psoriatic arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/27553214

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales

1 reference

https://pubmed.ncbi.nlm.nih.gov/27553214

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interleukin-17-positive mast cells contribute to synovial inflammation in spondylarthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/27553214

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides

1 reference

https://pubmed.ncbi.nlm.nih.gov/27553214

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on e

1 reference

https://pubmed.ncbi.nlm.nih.gov/27553214

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Brief report: enrichment of activated group 3 innate lymphoid cells in psoriatic arthritis synovial fluid

1 reference

https://pubmed.ncbi.nlm.nih.gov/27553214

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Classification criteria for psoriatic arthritis: development of new criteria from a large international study

1 reference

https://pubmed.ncbi.nlm.nih.gov/27553214

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1136/ANNRHEUMDIS-2016-209709

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34538249&oldid=1966656799"